<DOC>
	<DOCNO>NCT00301002</DOCNO>
	<brief_summary>The purpose study determine Alefacept effective treatment palmar plantar pustulosis .</brief_summary>
	<brief_title>Study Evaluate Efficacy Alefacept Treat Palmar Plantar Pustulosis</brief_title>
	<detailed_description>Palmar plantar pustulosis chronic , disable skin condition difficult treat since often recalcitrant current treatment associate high recurrence rate . This condition appear T lymphocyte mediate condition thought subtype psoriasis . Alefacept affect T cell activation induce apoptosis memory T cell . It show efficacious treatment psoriasis vulgaris may associate prolonged remission . There extremely limited experience use Alefacept Palmar Plantar Pustulosis . This pilot trial provide additional information concern use indication .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subjects must stable , moderate , severe severe palmar plantar pustulosis . Must minimum least 3 pustule 1 sole palm . Must give write informed consent . Subjects must 18 year age old . Adult Males nonpregnant , nonlactating female . Female subject childbearing potential must state use measure avoid conception active mean . Subjects must general good health skin disease , disease state physical condition would impair evaluation palmar plantar pustulosis would increase health risk study participation . Subjects must willing receive 15 mg IM injection Alefacept weekly 16 week . Female subject postmenopausal least 1 year , surgically sterile , willing practice effective contraception study . Nursing mother , pregnant woman woman plan become pregnant study exclude . Current enrollment investigational study subject receive type drug , biologic , nondrug therapy . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose investigational drug . Any subject whose CD4+ Tlymphocyte count study entry less low limit normal per reference laboratory . Treatment another investigational drug approve therapy investigational use within 28 day prior investigational drug administration . Treatment psoralen + ultraviolet A ( PUVA ) , systemic retinoids , systemic steroid , methotrexate , cyclosporine , azathioprine , thioguanine , etanercept , efalizumab , infliximab , adalimumab mofetil systemic immunosuppressant agent within 28 day prior investigational drug administration . Ultraviolet B ( UVB ) phototherapy within 14 day prior investigational drug administration . Treatment within 7 day topical agent ( e.g . tar , anthralin , calcipotriol , tazarotene , steroid ) might effect palmar plantar pustulosis . Known HIV , Hepatitis B C seropositivity tuberculosis infection . Significant abnormal chemistry , i.e . liver function test great 3 time upper limit normal . Allergy Alefacept component formulation . Known malignancy history malignancy within previous 5 year ( exception basal cell carcinoma skin squamous cell carcinoma situ skin treat evidence recurrence . ) Previous treatment alefacept .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>safety</keyword>
	<keyword>effectiveness</keyword>
	<keyword>Alefacept</keyword>
	<keyword>Palmar</keyword>
	<keyword>Plantar</keyword>
	<keyword>Pustulosis</keyword>
</DOC>